Clinical trials: Open-angle Glaucoma (OAG)
Glaucoma, Open-angle, Ocular Hypertension
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the intraocular pressure(IOP)-lowering efficacy of a combination IOP-lowering therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00311389
- Testing
- Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution, Latanoprost 0.005%/Timolol 0.005% ophthalmic solution
- Where
- Belgium
- Volunteers
- 408 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT® Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02325518
- Testing
- Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, Subject's habitual PGA monotherapy
- Where
- Japan
- Volunteers
- 218 people
- Sponsor
- Alcon, a Novartis Company
Glaucoma, Ocular Hypertension
Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension.
- Trial name
- NCT07641296
- Testing
- BIM-DRS Low Dose, BIM-DRS High Dose, SpyGlass IOL with silicone pads (no drug)
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Glaucoma, Ocular Hypertension
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
- Trial name
- JUPITER (NCT01895972)
- Testing
- Latanoprostene bunod
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Ocular Hypertension
A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate IOP response to experimental dose of Latanoprost- PPDS in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00855517
- Testing
- Latanoprost-PPDS
- Sponsor
- Mati Therapeutics Inc.
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers.
- Trial name
- NCT00716742
- Testing
- bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
- Where
- United States
- Volunteers
- 1,099 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the…
- Trial name
- NCT02140060
- Testing
- Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension
- Volunteers
- 327 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
Study of OMNI System in OAG (GEMINI)
This study will prospectively assess the clinical effect of ab-interno transluminal viscoelastic delivery and trabeculotomy performed using the OMNI Surgical System in combination with Cataract Extraction on intraocular pressure…
- Trial name
- NCT03861169
- Testing
- Transluminal viscoelastic delivery and trabeculotomy
- Where
- 15 sites in United States
- Volunteers
- 209 people
- Sponsor
- Sight Sciences, Inc.
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free [PF], fixed-dose combination [FDC] investigational product (IP) in subjects with open-angle…
- Trial name
- Firecrest (NCT07354516)
- Testing
- QLS-111-FDC, Latanoprost (0.005%)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Qlaris Bio, Inc.
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
AL-54478 Proof of Concept Study
The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01318252
- Testing
- AL-54478 0.005%, Latanoprost 0.005%, AL-54478 Vehicle
- Volunteers
- 64 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine if a combination of two drugs (bimatoprost and timolol) delivered to the surface of the eye over 10 weeks is better at lowering intraocular pressure (IOP) than either of the drugs…
- Trial name
- NCT02742649
- Testing
- Fixed Combination, Bimatoprost, Timolol
- Where
- Panama
- Volunteers
- 55 people
- Sponsor
- ForSight Vision5, Inc.
Open-angle Glaucoma, Ocular Hypertension
Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after six weeks of treatment in Caucasian and Japanese subjects.
- Trial name
- NCT00047606
- Testing
- IOP Lowering Medications
- Volunteers
- 84 people
- Sponsor
- Alcon Research
Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG).
- Trial name
- NCT01670266
- Testing
- ONO-9054
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ono Pharma USA Inc
Glaucoma, Eye Diseases
A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma
Prospective, unmasked, evaluation of the iStent in patients that have primary open-angle glaucoma (OAG). Stent implantation in one eye will be used for analysis, with medication added at 6 months, as required.
- Conditions
- Glaucoma, Eye Diseases, Glaucoma, Open-Angle
- Trial name
- SY (NCT00911924)
- Testing
- iStent
- Where
- 13 sites in Armenia, Austria and 4 more
- Volunteers
- 112 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach.
- Trial name
- NCT05411198
- Testing
- XEN45 (Glaucoma Gel Stent)
- Where
- 25 sites in United States, Australia
- Volunteers
- 74 people
- Sponsor
- AbbVie
Eye Diseases, Glaucoma, Open-Angle
Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)
Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.
- Conditions
- Eye Diseases, Glaucoma, Open-Angle, Glaucoma
- Trial name
- SL (NCT00913029)
- Testing
- iStent, latanoprost/timolol
- Where
- 16 sites in Armenia, Austria and 7 more
- Volunteers
- 192 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma or Ocular Hypertension
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular…
- Trial name
- NCT02981446
- Testing
- DE-117, Latanoprost ophthalmic solution
- Where
- Singapore
- Volunteers
- 370 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Ocular Hypertension, Open Angle Glaucoma
A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to test if latanoprost punctal plugs will reduce eye pressure in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT01229982
- Testing
- Latanoprost-PPDS
- Where
- Canada
- Volunteers
- 121 people
- Sponsor
- Mati Therapeutics Inc.
Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
iDose TR Administration in an Office-Based Surgery Setting
Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.
- Trial name
- NCT07816692
- Testing
- iDose TR (travoprost intracameral implant) 75 µg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glaukos Corporation